Chinese Journal of Tissue Engineering Research ›› 2018, Vol. 22 ›› Issue (21): 3281-3285.doi: 10.3969/j.issn.2095-4344.0895

    Next Articles

Interventions for severe craniocerebral injury by nasal administration of nerve growth factor combined with bone marrow stem cell mobilization

Wang Jun-yi1, Bu Xing-yao2, Gu Jian-jun3, Hu Sen1, Wang Bang-qing2, Gao Yu-shuai2   

  1. 1College of Basic Medicine of Henan University of Traditional Chinese Medicine, Zhengzhou 450046, Henan Province, China; 2Department of Neurology, 3Department of Intervention, Henan Provincial People’s Hospital, Zhengzhou 450006, Henan Province, China
  • Revised:2018-05-25 Online:2018-07-28 Published:2018-07-28
  • Contact: Bu Xing-yao, M.D., Chief physician, Professor, Master’s supervisor, Department of Neurology, Henan Provincial People’s Hospital, Zhengzhou 450006, Henan Province, China
  • About author:Wang Jun-yi, Master candidate, College of Basic Medicine of Henan University of Traditional Chinese Medicine, Zhengzhou 450046, Henan Province, China
  • Supported by:

    the Science and Technology Research Project of Henan Province, No. 122102310151, 201601016; the Medical Innovation Talent Project of Henan Province, No. 2011020120

Abstract:

BACKGROUND: Nasal administration is a new route of administration in which drugs can bypass the blood-brain barrier and act directly on the central nervous system. It not only has good brain targeting but also has the advantages of being non-invasive and convenient. Studies have shown that nerve growth factor (NGF) combined with bone marrow stem cell (BMSC) mobilization has a synergistic effect on brain injury.
OBJECTIVE: To observe the therapeutic effect of NGF combined with autologous BMSC mobilization via nasal administration and comprehensive rehabilitation for severe craniocerebral injury.
METHODS: Seventy-eight patients with traumatic brain injury from the Department of Neurosurgery of Henan Provincial People’s Hospital were selected and treated with NGF intramuscular injection (once a day, for continuous 28 days) combined with BMSC mobilization and comprehensive rehabilitation therapy as control group (n=39) or treated with NGF through the nasal administration (once a day, for continuous 28 days) combined with BMSC and comprehensive rehabilitation treatment as observation group (n=39). Therapeutic schedule for autologous BMSC mobilization was as follows: subcutaneous injection of recombinant human granulocyte colony-stimulating factor or recombinant human macrophage colony-stimulating factor alternately at 1 week after brain injury, once every 3 days, and oral administration of simvastatin tablets, 10 mg per day, for continuous 28 days. Two groups of patients continued to be treated with NGF for 3 months after discharge.
RESULTS AND CONCLUSION: At 28 days after treatment, the neurologic defect score in the observational group was slightly lower than that in the control group, but there was no significant difference between the two groups (t=0.429, P > 0.05). At 3 months after treatment, the score on the National Institutes of Health Stroke Scale was significantly better in the observational group than the control group (t=7.176, P < 0.05), and the score on the Glasgow Coma Scale Glasgow was also significantly higher in the observational group than the control group (P < 0.05). No obvious adverse event occurred in the two groups during the treatment and follow-up. To conclude, nasal administration of NGF combined with autologous BMSC mobilization and rehabilitation therapy can effectively promote the repair of severe craniocerebral injury and significantly improve the neurological function of the patients.

中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程

Key words: Craniocerebral Trauma, Nerve Growth Factor, Molecular Targeted Therapy, Mesenchymal Stem Cells, Tissue Engineering

CLC Number: